SUMMARY In osteoarthritis angiogenesis is involved in the reinitiation of cartilage growth and mineralisation. A number of heparin binding protein growth factors have been proposed as angiogenic factors, but none of them is specific for microvessel cells. Another factor which is specific for microvessel cells, is of low molecular weight and noif-protein has been called endothelial cell stimulating angiogenic factor (ESAF). ESAF has been found in significantly increased amounts in sera and synovial fluids of osteoarthritic patients and dogs. In addition to its angiogenic activity ESAF is able to activate neutral prometalloproteinases and to reactivate the active enzyme-inhibitor complex. The implication of these observations in the pathogenesis of osteoarthritis is discussed.
The view is now widely held that the osteoarthritic process is not solely a degenerative one. Rather, mechanical damage gives rise to some change in the nature of the articular cartilage, perhaps an altered cellular activity whose main purpose is regenerative but whose consequence is destructive. Conversely, it is arguable that altered cellular activity may also predispose the tissue to osteoarthritic changes. [1] [2] [3] Possible contenders for such early change involve the calcification of cartilage," the formation of new bone,1 5 and the penetration of new blood vessels.
Indeed it is difficult to separate bone neovascularisation and calcification as they normally occur together as linked processes. Implicit in this view of osteoarthritis (OA) is the idea that the reinitiation of cartilage growth and mineralisation are prerequisites of the osteoarthritic process (PD Byers, RA Brown, unpublished data).1 4 ESAF has also been shown to stimulate proliferation of pericytes (A Schor, personal communication).
In 1980 it was shown that two thirds of all synovial fluids from patients with OA contained amounts of ESAF sufficient to produce angiogenesis in an in vivo test system-namely, the chick chorioallantoic membrane. 9 10 Only about 15% of synovial fluids from patients with rheumatoid arthritis (RA) gave similar results.
In that study no consideration was given as to whether these few patients with RA were also suffering from OA. Subsequently, radiographic examination of those patients with RA and increased levels of ESAF suggested that there is an association with the presence of osteophytes. In view of the neovascularisation observed in RA the relative absence of ESAF suggests that inflammatory angiogenesis may be controlled through a mechanism distinct from that involved in bone growth. More recent work has shown that angiogenesis of RA is stimulated by a population of macrophages which secrete tumour necrosis factor alpha." 18 This factor has a molecular weight of 17 500 daltons and has been characterised and synthesised as a gene product. Macrophages are rare in OA, however, and even in inflammatory forms of OA such as crystal arthropathies the number of macrophages is far fewer than that found in rheumatoid arthritic joints.19
A remarkable property of ESAF is its ability to activate neutral prometalloproteinases: procollagenase, progelatinase, and to a lesser extent prostromelysin (J B Weiss, S C-S Ng, and B McLaughlin, unpublished data).20 21 All these enzymes have a key role in the degradation of connective tissue, including cartilage. Controlling the active forms of these enzymes is tissue inhibitor of metalloproteinase, which interacts with them to form inactive complexes.22 Reactivation of these enzymeinhibitor complexes has until now been considered to be a non-physiological proposition. Recent with ESAF has shown that it is not only present in excess in the synovial fluid of patients with OA but also in the serum of patients with active OA. 53 In dogs, after sectioning of the cruciate ligaments, an increase in serum ESAF levels similar to that seen in their synovial fluid also occurs (D Bennett et al, unpublished data). 52 The consequence of ESAF accumulation in joint effusions is uncertain at present. Preliminary work using intra-articular injections of purified ESAF indicates that ESAF produces no gross macroscopic changes and no loss of joint function. This is perhaps not surprising as such a regulator must itself be controlled and inactivated, particularly in the body fluids. Indeed, most of the ESAF in serum is reversibly bound to macromolecular carriers in adults, though there is an excess of ESAF to carrier in fetal serum. Accumulation of ESAF in the synovial fluid and serum probably represents a stage in its clearance from the joint. Consequently, its accumulation would indicate past activity in the cartilage rather than a stimulus to new activity, or changes with pathological consequences.
If ESAF does indeed work through its ability to activate procollagenase and progelatinase, and thus to create a space for new blood vessels to move into the matrix, then it is not improbable that some inhibitors of collagenase and gelatinase could also be acting as inhibitors of ESAF. The tissue inhibitor of metalloproteinase, which is the major inhibitor so far described, is not capable of inhibiting the angiogenic activity of ESAF either in in vivo or in vitro tests (unpublished observations). Specific inhibitors of angiogenesis are, however, present in cartilage and vitreous,31 32 and one of these (in vitreous) also inhibits collagenase. Platelet factor 4 is another example of an inhibitor of collagenase and angiogenesis.54 55 The presence in OA cartilage of a low molecular weight activator of collagenolytic enzymes, in transit diffusion from bone to synovial fluid, may be seen as a possible and indeed likely contributor to the degradative process in that condition. When the structure of ESAF is known it is not unlikely that analogues may have a therapeutic role.
In conclusion, the role of neovascularisation in the pathogenesis of OA is inevitably bound up with cartilage calcification and ossification. As evidence from other sources has implicated calcific changes and bone growth with joint degeneration it is perhaps not surprising that ESAF is also present. It is exciting that by analogy with growth plate neovascularisation it is possible to propose a mechanism by which cartilage lysis and capillary invasion (and by implication calification) are regulated through chondrocyte production of ESAF. There still remains the question of at which stage in the process of osteoarthritic joint degeneration neovascularisation is important-early, as a precipitating factor, or, later, during the extensive growth of new bone. 
